This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bijman, M. N.A. Articles by Boven, E. Search for Related Content PubMed PubMed Citation Articles by Bijman, M. N.A. Articles by Boven, E.

Research Articles: Therapeutics

Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton

¹ Departments of Medical Oncology and ² Physiology, Vrije Universiteit Medical Center, Amsterdam, the Netherlands

Correspondence: Epie Boven, Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. Phone: 31-20-444-4336; Fax: 31-20-444-4079. E-mail: e.boven{at}vumc.nl

Conventional anticancer agents may display antiangiogenic effects, but the underlying mechanism is poorly understood. We determined the antiangiogenic properties of cisplatin, doxorubicin, and the microtubule-targeting agents docetaxel, epothilone B, and vinblastine at concentrations not affecting cell proliferation. We also assessed tubulin and actin morphology and the activity of two key molecules in cell motility, the small Rho GTPases Cdc42 and Rac1. The highest non-toxic concentration (HNTC) of each drug was defined as the concentration inhibiting a maximum of 10% human umbilical vein endothelial cell growth on a 1-hour drug exposure, being for cisplatin 10 µmol/L, doxorubicin 100 nmol/L, docetaxel 10 nmol/L, epothilone B 1 nmol/L, and vinblastine 10 nmol/L. Comparative endothelial cell functional assays using HNTCs for an exposure time of 1 hour indicated that endothelial cell migration in the wound assay, endothelial cell invasion in a transwell invasion system, and endothelial cell formation into tubelike structures on a layer of Matrigel were significantly inhibited by docetaxel, epothilone B, and vinblastine (P < 0.05), but not by cisplatin and doxorubicin. Docetaxel was slightly more efficient in the inhibition of endothelial cell motility than epothilone B and vinblastine. Fluorescence microscopy revealed that only the microtubule-targeting agents affected the integrity of the tubulin and F-actin cytoskeleton, which showed disturbed microtubule structures, less F-actin stress fiber formation, and appearance of nuclear F-actin rings. These observations were associated with early inhibition of Rac1 and Cdc42 activity. In conclusion, HNTCs of microtubule-targeting agents efficiently reduce endothelial cell motility by interference with microtubule dynamics preventing the activation of Rac1/Cdc42 and disorganizing the actin cytoskeleton. [Mol Cancer Ther 2006;5(8):2348–57]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 5/ 2/06; revised 6/13/06; accepted 7/11/06.

This article has been cited by other articles:

				S. Honore, A. Pagano, G. Gauthier, V. Bourgarel-Rey, P. Verdier-Pinard, K. Civiletti, A. Kruczynski, and D. Braguer Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites Mol. Cancer Ther., July 1, 2008; 7(7): 2080 - 2089. [Abstract] [Full Text] [PDF]

				Y. H. Zeidan, R. W. Jenkins, and Y. A. Hannun Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway J. Cell Biol., April 21, 2008; 181(2): 335 - 350. [Abstract] [Full Text] [PDF]